Shots: The companies will initiate P-I/II study evaluating the safety and preliminary efficacy of BBP-398 in combination with both Opdivo as dual therapy & Opdivo + KRASG12C inhibitor as triplet […]readmore
Tags : Clinical Collaboration
Shots: Linnaeus will conduct 6 additional P-II cohorts evaluating LNS8801 + Keytruda in several cancer indications while the companies are currently evaluating the combination in patients who had previously responded […]readmore
Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate to evaluate PK/PD & preliminary efficacy of […]readmore
Shots: The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701, Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for […]readmore
Shots: AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer AVEO plans to initiate the […]readmore
Shots: The agreement involves onset of P-I trial including Pediatric Patients with solid tumors & acute leukemia receiving ALRN-6924 as a monotx & in combination with cytarabine With the above […]readmore